Tetraphase Pharma's (TTPH) IGNITE2 Phase 3 Missed Primary Endpoint in cUTI
Tweet Send to a Friend
Tetraphase Pharma (NASDAQ: TTPH) announced that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
